Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride Ion SCHEMBL1708173 | 0.96 | — | — | |
| Ammonia Solution, Strong SCHEMBL2892185 | 0.96 | — | — | |
| SCHEMBL29167943 | 0.96 | SLC34A1 (0.50) | — | |
| Ammonia Solution, Strong SCHEMBL28500032 | 0.92 | — | — | |
| Lithium Ion SCHEMBL28390201 | 0.91 | — | — | |
| Ammonia Solution, Strong SCHEMBL7594155 | 0.89 | SLC34A1 (0.53) | — | |
| Phosphoric Acid SCHEMBL4931344 | 0.87 | SLC34A1 (0.50) | — | |
| Phosphoric Acid SCHEMBL29078233 | 0.87 | SLC34A1 (0.50) | — | |
| SCHEMBL28271386 | 0.87 | SLC34A1 (0.50) | — | |
| Lithium Ion SCHEMBL29135346 | 0.87 | SLC34A1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 381 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622567-B1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME (US) | 2013-07-24 | — | — | EP | claimed |
| JP-4832303-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| EP-1622567-A4 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO INC (US) | 2009-04-29 | — | — | EP | claimed |
| EP-1434786-A4 | ANDROSTANE 17-BETA-CARBOXAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2009-03-25 | — | — | EP | claimed |
| US-20080139630-A1 | N-(2-Benzyl)-2-Phenylbutanamides As Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2008-06-12 | — | — | US | claimed |
| US-20080124402-A1 | N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | claimed |
| US-20080125399-A1 | 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2008-05-29 | — | — | US | claimed |
| EP-1641535-A4 | 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2008-05-14 | — | — | EP | claimed |
| EP-1641761-A4 | 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2008-05-14 | — | — | EP | claimed |
| EP-1641464-A4 | 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2008-05-14 | — | — | EP | claimed |
| WO-2003029268-A1 | ANDROSTANE 17-BETA-CARBOXAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-04-10 | — | — | WO | claimed |
| WO-2003026568-A2 | ANDROSTANES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-04-03 | — | — | WO | claimed |
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | claimed |
| WO-2003011302-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | claimed |
| JP-2002521440-A | — | — | 2002-07-16 | — | — | JP | claimed |
| US-20020039567-A1 | Methods of treating bone or cartilage conditions by the administration of creatine | ALZCHEM TROSTBERG GMBH (DE) | 2002-04-04 | — | — | US | claimed |
| EP-1100488-A1 | USE OF CREATINE COMPOUNDS FOR TREATMENT OF BONE OR CARTILAGE CELLS AND TISSUES | Synergen AG (CH) | 2001-05-23 | — | — | EP | claimed |
| WO-2000006150-A1 | USE OF CREATINE COMPOUNDS FOR TREATMENT OF BONE OR CARTILAGE CELLS AND TISSUES | SYNERGEN AG (CH) | 2000-02-10 | — | — | WO | claimed |
| US-4693888-A | ANTIBODY OBTAINED BY IMMUNIZING MAMMAL WITH STREPTOCOCCUS MUTANS DERIVED ANTIGEN, AND SYNERGIST | LION CORPORATION (JP) | 1987-09-15 | — | — | US | claimed |
| US-4335102-A | WATER-SOLUBLE AND WATER-INSOLUBLE STANNOUS COMPOUNDS | LION CORPORATION (JP) | 1982-06-15 | — | — | US | claimed |